Mutant tubulins may help reduce tau-related damage in Alzheimer's disease.
Official title: Mutant Tubulins Confer Resistance to Pathological Tau
Funded at Seattle Inst for Biomedical/clinical Res · NIH-11042274 · Data updated 2026-11-12
This study is looking at how certain changes in tubulin proteins might help protect brain cells from damage caused by tau, a protein linked to Alzheimer's and similar diseases, using tiny worms and brain cells to find new ways to treat these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $249,000 |
| NIH project number | 7R00AG073455-04 |
| Project ID | NIH-11042274 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease or related tauopathies.
✕Less likely to help
Patients with tauopathies not related to Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates how mutant tubulin proteins can influence the effects of pathological tau, a protein associated with Alzheimer's disease and other neurodegenerative conditions. By using model organisms like C. elegans and mammalian neurons, the study aims to understand how these mutations can alter the interactions between tau and microtubules, potentially reducing neurodegeneration. The research employs a combination of genetic manipulation, in vitro systems, and cellular assays to explore these mechanisms. The ultimate goal is to uncover new insights that could lead to effective treatments for tauopathies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Alzheimer's disease and other tau-related disorders.
How similar studies have gone: While the approach of using mutant tubulins is innovative, similar studies have shown promise in understanding tau-related mechanisms, indicating potential for success.
Where this research is happening
-
Seattle Inst for Biomedical/clinical Res
Seattle, United States Active
Researchers
- Principal investigator: Benbow, Sarah Jean Zimmerman — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Benbow, Sarah Jean Zimmerman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.